EFFECTS OF SOY AND DAIRY MILK ON LIPIDS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。背景：1995年的一项荟萃分析得出结论，根据当时可获得的文献，食用大豆蛋白可显著降低血清胆固醇。从那时起，文献中增加了更多的研究，有些是肯定的，有些不是。现在有一些人认为，降胆固醇的效果可能是某些大豆产品中发现的特定亚基的结果。这个亚基在某些加工技术中丢失了，因此可能解释了研究之间的差异。此外，大豆蛋白的降胆固醇效果可能只在那些开始研究的低密度脂蛋白(低密度脂蛋白)-胆固醇水平&160毫克/分升的人身上才能看到。目的：本研究的主要目的是比较两种大豆饮料，一种含有相关亚基，另一种不含亚基，与对照低脂牛奶饮料的潜在降胆固醇效果。测量的主要结果将是血脂。研究对象：血清低密度脂蛋白-胆固醇水平升高(160-220 mg/dL)的个体将参加这项随机交叉试验。除了胆固醇水平升高外，这些人都是低风险参与者。低风险将被定义为Framingham Risk Score&lt；10%(表示发生“硬”冠心病(CHD)事件的10年风险；基于性别、年龄、低密度脂蛋白、高密度脂蛋白、血压、糖尿病和吸烟)。方法：所有参与者都将在四周的时间里饮用所有三种牛奶饮料，但顺序不同。在每个饮料阶段的开始、中期和结束时将测量血脂。此外，胰岛素敏感性将在研究开始时进行一次评估，然后在每个饮料阶段结束时进行评估

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. BACKGROUND: A 1995 meta-analysis concluded that, based on the literature avaliable at that time, soy protein consumption lead to a significant decrease in serum cholesterol. Since that time, much more research has been added to the literature, some positive, some not. There is now some belief that the cholesterol-lowering effect might be the result of a specific subunit found in some soy products. This subunit is lost during some processing techniques, thus potentially explaining the discrepancies between studies. In addition, the cholesterol-lowering effect of the soy protein may only be seen in those individuals who begin the study with low density lipoproteins (LDL)-cholesterol levels > 160 mg/dL. OBJECTIVE: The primary objective of this study is to compare the potential cholesterol-lowering effects of two soy beverages, one with the subunit in question and one without, to a control beverage of low-fat dairy milk. The primary outcome measured will be serum lipids. SUBJECTS: Individuals with elevated serum LDL-cholesterol levels (160-220 mg/dL) will participate in this randomized cross-over trial. Aside from elevated cholesterol levels, these will be low-risk participants. Low-risk will be defined as a Framingham risk score of <10% (indicates 10-year risk of a "hard" coronary heart disease (CHD) event; based on gender, age, LDL, high density lipoproteins (HDL), blood pressure, diabetes, and smoking). METHODS: All participants will consume all three milk beverages for four weeks each, but in different orders. Serum lipids will be measured at the beginning, middle, and end of each beverage phase. In addition, insulin sensitivity will be assessed once at the beginning of the study, and then at the end of each beverage phase